Article
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
BMC cancer - 5 Aug 2017
De Benedittis Caterina, Papayannidis Cristina, Venturi Claudia, Abbenante Maria Chiara, Paolini Stefania, Parisi Sarah, Sartor Chiara, Cavo Michele, Martinelli Giovanni, Soverini Simona
Abstract excerpt
BACKGROUND: The treatment of Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL) patients who harbor the T315I BCR-ABL1 mutation or who have two or more mutations in the same BCR-ABL1 molecule is particularly challenging since first and second-generation Tyrosine Kinase Inhibitors (TKIs) are ineffective. Ponatinib, blinatumomab, chemotherapy and transplant are the currently available options...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.